

Inmedix to Discuss Breakthrough Fast/Fail Development for Autoimmune Disease Therapeutics at 2016 Life Science Innovation Northwest

CEO Andrew Holman will review how part of brain that controls stress is key to determining treatment outcomes and even who will become afflicted

Seattle, WA- May 18, 2016--Inmedix (www.inmedix.com), a medical diagnostic company combining brain and immunology research to determine treatment outcomes and predictors for rheumatoid arthritis and other autoimmune diseases, today announced that CEO Andrew Holman, MD, will be a podium presenter at 2016 Life Science Innovation Northwest (LSINW), being held June 1-2, 2016 at the Washington State Convention Center. His presentation, part of the Medical Technology panel, is scheduled for Wednesday June 1st at 2:10 pm in room #611.

Dr. Holman will suggest that drug companies could save an enormous amount of time and resources for certain clinical trial testing if they could determine overall patient response based on smaller samples. He'll share how his company has discovered a tool to do just that. Going a step further- Dr. Holman says this tool has not only determined treatment outcomes but has shown promise in predicting who will become afflicted with rheumatoid arthritis. The company is currently working on regulatory FDA clearance and additional research in other autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis.

Dr. Holman and his team have discovered that a little talked about section of the brain that controls stress and aggravates autoimmune diseases, the Autonomic Nervous System, can be measured via a device the company created- Inmedix ANS Neuroscan™. This 5-minute ECG-based assessment accurately reveals an individual's ANS status to identify those most likely to respond to immunosuppressive therapies. Preferentially enrolling these subjects into new studies can potentially jumpstart the assessment of a promising new treatment.

New drug discovery, development and validation through clinical trials is an exceptionally costly and slow process. By initially reducing the number of study participants unlikely to respond to any therapeutic, a company can learn much more quickly and with fewer study patients and less cost, whether or not its new drug candidate is viable.

Inmedix is focused on a dual purpose for ANS Neuroscan testing; to identify patients most likely to respond to current treatment options and guide clinician decision-making, and also accelerate development of new therapeutics for patients less responsive to currently available options.

“By considering how the brain controls immune function, Inmedix offers a novel opportunity for patients, clinicians and pharmaceutical companies to diminish the tragic consequences of rheumatoid arthritis and other autoimmune diseases,” says Inmedix CEO and rheumatologist

Andrew J. Holman, M.D. “This is an exciting time for our team as we embark on a funding journey to help make bring our technology to market.”

[2016 Life Science Innovation Northwest](#) is North America’s largest fully-integrated Life Science exposition. This event connects world-class industry leaders and showcases the Pacific Northwest as a global center for life science advancement.

About Inmedix, LLC

Seattle-based biotech Inmedix is committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the autonomic nervous system (ANS). Inmedix’s ANS Neuroscan is the leading heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, beginning with U.S. patients with rheumatoid arthritis (RA). The company’s science and technology raises therapeutic outcomes and retention so that patients no longer need to cycle through failure of one biologic after another. Visit www.inmedix.com

Media contact

Rae Marie Gleason

714-423-4863

Raemarie.gleason@inmedix.com